Study of Atomoxetine and OROS Methylphenidate to Treat Children and Adolescents Ages 6-17 With ADHD
Status:
Completed
Trial end date:
2007-12-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the safety, effectiveness, and tolerability of
atomoxetine and OROS methylphenidate, taken together, in the treatment of ADHD in children
and adolescents ages 6-17.